Kornimate/medical-research-clean huggingface dataset:
application of al18f-nota-fapi pet/ct in malignant tumors expressing fibroblast-activated proteins

Conditions: Malignancy

Summary: this is an open-label whole-body pet/ct study for investigating the value of al18f-nota-fapi pet/ct in patients with malignant tumors expressing fibroblast-activated proteins

tumour tissue includes tumour cells as well as stromal cells (vascular cells, inflammatory cells, fibroblasts etc.). activated fibroblasts are present not only in tumours but also in wound healing and diseases with stromal remodelling, such as chronic inflammation, myocardial infarction and liver and lung fibrosis.there is a correlation between fap expression and tumour microvascular density and fap expression is strongly associated with poor prognosis in a variety of tumours (e.g. colon, pancreatic, ovarian and hepatocellular carcinoma).over 90% of fap-positive cancer-associated fibroblasts are found in epithelial tumours, whereas fibroblasts in normal tissues rarely or even do not express fap, making fap a potential target for imaging and treatment of various malignancies. al18f-nota-fapi is a posionuclide 18f-labelled tumour developer targeting fap. current domestic and international studies have shown that it has good stability and high fap specificity, and shows excellent imaging quality and tumour detection in tumour-bearing mice and cancer patients, and can be used as a broad-spectrum tumour developer for clinical pet/ct imaging for diagnosis and efficacy assessment of tumour patients.

Eligibility criteria:
inclusion criteria: * patients with suspected or clearly diagnosed malignant tumors expressing fibroblast-activated proteins * signed written consent. * willing and able to cooperate with all projects in this study. exclusion criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Keywords: malignant tumors expressing fibroblast-activated proteins
study comparing adapalene/bp gel to epiduo® forte and both to a placebo control in treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: bioequivalence with clinical endpoints.

randomized, double-blind, placebo-controlled, multiple-site, parallel design, bioequivalence with clinical endpoints.

Eligibility criteria:
inclusion criteria: * healthy male or non pregnant female aged ≥ 12 and ≤ 40years with a clinical diagnosis of acne vulgaris. exclusion criteria: * female subjects who are pregnant, nursing or planning to become pregnant during study participation
identification of key blood molecular markers for immunotherapy

Conditions: Squamous Cell Carcinoma; Adenocarcinoma; Neoplasms

Summary: to identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with cancerous tumors based on biopsy or other clinical observations. 2. patients diagnosed with non-cancerous tumors based on biopsy or other clinical observations. 3. normal volunteers who do not have cancer or other medical conditions that may affect survival. exclusion criteria: 1. patients will be excluded if, upon clinical observation, they are under a severe septic or inflammatory condition. in these conditions, human body immune response against sepsis or inflammation should be the predominant response, and may shield or block the immune response against tumors. 2. patients will be excluded if, upon clinical observation, they are under extremely illness situation like myocardial infarction. in such a case, the immune findings may be altered. 3. patients will be excluded if, upon looking through their medical records, significant information required for data analysis is missing. this is because that patients' medical records will help us connect our research findings with their clinical observations, and further provide guidelines for subsequent treatment options.
safety study in patients with scalp psoriasis suppression following maximal use treatment with topical product

Conditions: Scalp Psoriasis

Summary: an open-label, safety study to assess the potential for adrenal suppression following maximal use dsxs topical product (taro pharmaceuticals u.s.a., inc.) in patients with moderate to severescalp psoriasis

* evaluate the potential of dsxs topical product to suppress hpa axis function in patients with moderate to severe scalp psoriasis. * evaluate the efficacy parameters and adverse event (ae) profiles of dsxs topical product administered to patients with moderate to severe scalp psoriasis.

Eligibility criteria:
inclusion criteria: * male or non-pregnant, non-lactating females 12-17 years of age. exclusion criteria: * females who are pregnant, nursing, planning to become pregnant during the duration of the study, or if of child-bearing potential and sexually active and not prepared to use appropriate contraceptive methods to avoid pregnancy.
a clinical study to evaluate safety & efficacy of the combination of aliskiren, valsartan & hydrochlorothiazide in diabetic hypertensive nonresponder patients

Conditions: Hypertension; Diabetes

Summary: to evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not adequately responsive to the combination of valsartan and hydrochlorothiazide


Eligibility criteria:
inclusion criteria * patients with essential hypertension * patients with a documented diagnosis of type 1 or type 2 diabetes mellitus. * patients who are eligible and able to participate in the study exclusion criteria * severe hypertension * uncontrolled diabetes type i and ii * history or evidence of a secondary form of hypertension * history of hypertensive encephalopathy or cerebrovascular accident. other protocol-defined exclusion criteria may apply.

Keywords: hypertension, diabetes, aliskiren, blood pressure, valsartan, hydrochlorothiazide
a study of vemurafenib in previously treated patients with metastatic melanoma

Conditions: Malignant Melanoma

Summary: this open-label single arm study will assess the efficacy, safety and tolerability of vemurafenib in previously treated patients with metastatic melanoma. patients will receive oral vemurafenib \[rg7204; plexxikon: plx4032\] at a dose of 960 mg b.i.d. continuously until disease progression or withdrawal from study and will be assessed at regular intervals for tumour response and tolerability. target sample size is \<100 patients.


Eligibility criteria:
inclusion criteria: * adult patients \>/=18 years of age * histologically confirmed metastatic melanoma (stage iv, ajcc) * patients must have completed and failed at least one prior standard of care regimen (e.g. dtic, temozolomide, etc.) * braf v600e positive mutation (by roche codx braf mutation assay) * measurable disease by recist criteria * negative pregnancy test and, for fertile men and women, effective contraception during treatment and for 6 months after completion exclusion criteria: * active cns metastases on ct/mri within 28 days prior to enrollment * history of or known carcinomatous meningitis * previous treatment with braf (sorafenib allowed) or mek inhibitor * cardiac dysrhythmias \>2 nci ctcae or treatment with drugs with dysrhythmic potential * uncontrolled hypertension(\>150/100mmhg) despite optimal medical therapy * infectious disease including hiv, hbv and hcv
an indian post marketing study of mealtime insulin, fiasp®, to evaluate its safety and effectiveness in patients with diabetes mellitus in routine clinical practice

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this study is to investigate the effects of fiasp®, a mealtime insulin, in patients with diabetes mellitus. the purpose of this study is to collect information about fiasp®, which is prescribed to the participants by their doctors. participants will administer fiasp® as prescribed by their doctors. the study will last for about 6 months.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any study-related activities. study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * male or female, age equal to or above 18 years at the time of signing the informed consent. * patients diagnosed with diabetes mellitus. * patients scheduled to start treatment with fiasp® based on the clinical judgement of their treating physician. exclusion criteria: * known or suspected hypersensitivity to study product(s) or related products. * patients on or likely to use insulin pump therapy during the study period * previous participation in this study. participation is defined as having given signed informed consent. * mental incapacity, unwillingness or language barriers hindering adequate understanding or cooperation. * participation in any clinical study of an approved or non-approved investigational medicinal product within 1 month before treatment start. * any disorder which in the opinion of the treating physician may jeopardise the patient's safety or compliance with the protocol.
sundt™ carotid shunt retrospective post market clinical follow-up study (pmcf)

Conditions: Carotid Artery Stenosis

Summary: the primary objective of this study is to retrospectively investigate the safety and efficacy of the integra sundt™ carotid shunt during endarterectomy procedures.


Eligibility criteria:
inclusion criteria: * between the ages of 18-80 years old * have undergone carotid endarterectomy with any integra sundt™ carotid shunt on or before date of study initiation * availability of records on post-operative imaging of the carotid artery either by carotid duplex ultrasound or angiogram exclusion criteria: * insertion of a carotid shunt at the site of an infection
comparison of high flow nasal cannula and standard face mask oxygen therapy in children with bronchiolitis

Conditions: Acute Bronchiolitis

Summary: the study aims to compare the efficacy of two different oxygenation methods on decrease respiratory rate, heart rate, and clinical respiratory score in children with moderate to severe bronchiolitis requiring oxygen therapy. 1. standard face mask oxygen therapy (st-fmot) 2. high-flow nasal cannula oxygen therapy (hfncot)

bronchiolitis is the most common cause of hospitalization for children under one year of age and, caused by respiratory viruses. although several medications and interventions studied for bronchiolitis treatment, hydration and oxygenation are the main treatments. high-flow nasal cannula oxygen therapy (hfncot) has been widely used to provide respiratory support in children with acute respiratory diseases. patients had earlier improvement with hfncot to decrease the respiratory rate and respiratory effort than patients with standard low-flow oxygen therapy (sot). hfncot therapy reduced more effective in heart rate, respiratory effort, and length of supportive oxygen treatment (loot) compared with sot. however, the length of hospital stay (los) and feeding ability had better consequences in patients with moderate and severe bronchiolitis treated with hfncot. another published study shows that in infants with acute bronchiolitis, which required oxygen therapy, there was no significant difference between therapy groups in terms of loot, los, and admission to the intensive care unit (icu). hfncot was more efficient than sot and reduced the rate of intubation/invasive ventilation in severe bronchiolitis management. despite these beneficial effects of hfncot, it was not recommended by international guidelines yet. however, well designed, prospective randomized controlled trials are still needed to use this therapy in the wards.

Eligibility criteria:
inclusion criteria: * children aged between 1-24 months applied with moderate and severe bronchiolitis requiring supplemental oxygen were eligible for the study. * the severity of bronchiolitis was assessed according to the clinical respiratory score (crs) of liu et al. (5). the patients with crs ≥5 were included. * peripheral oxyhemoglobin saturation is \< 92%. exclusion criteria: * children admitted to the icu for urgent invasive mechanical ventilation; * those who received standard oxygen therapy (sot) or hfncot at other facilities before arrival; * those with an underlying medical condition (such as congenital heart disease, chronic lung disease, neuromuscular disease, metabolic disease, or immunocompromised); * those who had a craniofacial malformation, an upper airway obstruction, pneumothorax, or nasal trauma, and missing parental consent or a refused permission of the participant.

Keywords: acute bronchiolitis high flow nasal cannula standard face mask
effects of inspiratory muscle training on diaphragm thickness, respiratory muscle strength and balance in dancers.

Conditions: Athletic Injuries

Summary: dance is a performing art form consisting of sports and art intertwined and complex dynamic choreographic figures were handled aesthetically and physically of narrative. scientific studies are insufficient on dance and health and performance of dancers in the literature although dance is the most used type of art and sport in all societies and for all age groups. it is seen that the core stabilization (central forces) of the dancers is insufficient when the current studies were examined, this insufficient stabilization causes biomechanical changes in the trunk, and indirectly affects the lower extremities. consequently, insufficient stabilization was shown to be caused impairment of force generation and injuries. in addition, lack of core stabilization of dancers may cause impairment in balance and postural control. therefore, dancers need a good postural control with provided by an effective core stabilization training in order to exhibit a successful and healthy performance. it is shown that inspiratory muscle training (imt) improves diaphragm strength and diaphragm thickness. considering the relation between diaphragm muscle forming the upper (ceiling) part of the core area, and balance, imt may also have an impact on postural control and balance alongside the standard clinical parameters such as respiratory muscle strength and diaphragm thickness in dancers. thus, the aim of this study was to investigate the effects of inspiratory muscle training on diaphragm thickness, postural stability, balance, respiratory muscle strength in dancers.


Eligibility criteria:
inclusion criteria: * dancer (for least two years) * stable clinical condition (no injury in last 2 months) exclusion criteria: * documented diagnosis of vestibular, neurological or orthopedic disorders which may affect balance and mobility * having of chronic pulmonary disease

Keywords: inspiratory muscle training diaphragm respiratory muscle strength balance dancer
estimation of pentrexin-3 levels in gcf and saliva of patients with periodontal disease

Conditions: Chronic Periodontitis; Aggressive Periodontitis

Summary: subjects were selected from the outpatient clinic, department of oral medicine and periodontology, faculty of oral and dental medicine, cairo university. ten healthy control subjects presented with clinically healthy periodontium. ten patients who had plaque induced gingivitis. ten patients who had generalized chronic periodontitis. ten patients who had generalised aggressive periodontitis. pentraxin-3 levels were evaluated in gcf and saliva of all subjects included in this study with elisa technique.

the study population consisted of 4 groups of forty patients selected as follows: group 1 - healthy controls: ten healthy control subjects presented with clinically healthy periodontium. control subjects had to meet the following criteria for inclusion: probing depth less than 3mm, no clinical attachment loss, no bleeding on probing, with gingival and plaque index 0-1. group 2 - plaque induced gingivitis patients: ten patients who had plaque induced gingivitis characterized by the presence of any of the following clinical signs: redness and edema of the gingival tissue, bleeding upon provocation, changes in contour and consistency, presence of calculus and/or plaque, with no clinical attachment loss nor radiographic evidence of bone loss. group 3 - chronic periodontitis group: ten chronic moderate to severe periodontitis patients selected according to the criteria currently adopted by armitage 1999. moderate destruction is generally characterized by periodontal probing depths up to 6 mm with clinical attachment loss of up to 4 mm. advanced destruction is generally characterized by periodontal probing depths greater than 6 mm with attachment loss greater than 4 mm. radiographic evidence of bone loss is apparent, increased tooth mobility may be present. group 4 - aggressive periodontitis group: ten patients suffering generalized aggressive periodontitis, patients were less than 35 years of age and had generalized interproximal attachment loss affecting at least 3 permanent teeth other than the first molars and incisors with at least one site each with pd and cal \>5 mm, attachment loss occurs in pronounced episodic periods of destruction, and there is familial aggregation (subjects were asked if they had at least one other member of the family presenting or with a history of periodontal diseases). gcf and saliva samples were collected for all patients. pentraxin-3 levels were evaluated in gcf and saliva of all subjects included in this study with elisa technique.

Eligibility criteria:
inclusion criteria: * patients with plaque induced gingivitis * patients with chronic periodontitis * patients with aggressive periodontitis exclusion criteria: * patients with any systemic disease according to cornell medical index (1968). * patients taking any medications or antibiotics in the last 3 months. * current or former smoker patients. * pregnant females.

Keywords: saliva gcf pentraxin-3
a study assessing the efficacy and safety of sarilumab added to mtx in japanese patients with moderately to severely active rheumatoid arthritis (saril-ra-kakehasi)

Conditions: Rheumatoid Arthritis

Summary: primary objective: -to demonstrate that sarilumab added to methotrexate (mtx) reduce signs and symptoms of rheumatoid arthritis (ra) in japanese ra participants with an inadequate response to mtx. secondary objective: -to assess the safety of sarilumab added to mtx in japanese ra participants with an inadequate response to mtx.

the total duration of study was expected up to 62 weeks (screening period of 4 weeks, treatment period of 52 weeks, and a 6-week post treatment observation).

Eligibility criteria:
inclusion criteria: * diagnosis of ra, according to the american college of rheumatology/the european league against rheumatism (acr/eular) 2010 rheumatoid arthritis classification criteria with \>=3 months disease duration. * moderately to severely active ra defined as: * at least 8 of 68 tender joints and 6 of 66 swollen joints at screening visit. * high sensitivity c-reactive protein (hs-crp) \>=6mg/l at screening visit. exclusion criteria: * participants \ 75 years of age. * treatment with any disease-modifying antirheumatic drug (dmard) other than mtx or biologic agent without the appropriate off-drug period prior to screening. * prior treatment with anti-interleukin-6 (anti-il-6) or anti-interleukin-6 receptor (il-6r) antagonist therapies, including but not limited to tocilizumab or sarilumab. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
difference between progestin primed ovarian stimulation protocol and antagonist protocol

Conditions: Infertility Assisted Reproductive Technology

Summary: compare the effectiveness and safety of the progestin primed ovarian stimulation (ppos) protocol versus the antagonist protocol in hyper-responder patients scheduled for a freeze-all policy

infertility treatments have evolved significantly over the past few decades, with various protocols being developed to optimize ovarian stimulation in assisted reproductive technology (art). among these protocols, the progestin-primed ovarian stimulation (ppos) and the antagonist protocols have gained prominence, especially in hyper-responders who are scheduled for a freeze-all policy. hyper-responders are patients who produce an excessive number of eggs in response to ovarian stimulation, which increases the risk of ovarian hyperstimulation syndrome (ohss), a potentially severe complication . the ppos protocol involves the administration of progestins to suppress the premature luteinizing hormone (lh) surge during ovarian stimulation, thereby providing a controlled environment for follicle development. this method has been found to be effective in reducing the risk of ohss and improving clinical outcomes . on the other hand, the antagonist protocol employs gonadotropin-releasing hormone (gnrh) antagonists to prevent the lh surge, offering a more immediate suppression compared to progestins . a freeze-all policy, where all viable embryos are frozen for future use rather than being transferred immediately, is often recommended for hyper-responders to further minimize the risk of ohss . this approach allows for the transfer of embryos in a more physiologically normal uterine environment, potentially improving implantation rates and pregnancy outcomes . this study aims to compare the effectiveness and safety of the ppos protocol versus the antagonist protocol in hyper-responder patients scheduled for a freeze-all policy. by examining outcomes such as the number of retrieved oocytes, incidence of ohss, and pregnancy rates, this research seeks to provide insights into the optimal ovarian stimulation strategy for this specific patient population.

Eligibility criteria:
inclusion criteria: • all hyper responder patients according to olivera equation for overian response peridiction index exclusion criteria: * all normal and poor responder patients according to olivera equation for overian response peridiction index. * sever male factor infertility

Keywords: progestin primed ovarian stimulation